Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1973 1
1975 5
1979 1
1981 3
1983 1
1984 2
1985 3
1986 3
1987 3
1988 2
1989 4
1990 4
1991 5
1992 6
1993 7
1994 9
1995 5
1996 8
1997 7
1998 7
1999 6
2000 12
2001 6
2002 8
2003 10
2004 11
2005 13
2006 12
2007 14
2008 17
2009 9
2010 9
2011 10
2012 9
2013 6
2014 5
2015 4
2016 3
2017 3
2018 7
2019 7
2020 8
2021 13
2022 9
2023 7
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

282 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team. Bril V, et al. Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. Lancet Neurol. 2023. PMID: 37059507 Clinical Trial.
Anti-Islet Autoantibodies in Type 1 Diabetes.
Kawasaki E. Kawasaki E. Int J Mol Sci. 2023 Jun 11;24(12):10012. doi: 10.3390/ijms241210012. Int J Mol Sci. 2023. PMID: 37373160 Free PMC article. Review.
Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, Kadowaki T; J-DOIT3 Study Group. Ueki K, et al. Lancet Diabetes Endocrinol. 2017 Dec;5(12):951-964. doi: 10.1016/S2213-8587(17)30327-3. Epub 2017 Oct 24. Lancet Diabetes Endocrinol. 2017. PMID: 29079252 Clinical Trial.
ZnT8 and type 1 diabetes.
Kawasaki E. Kawasaki E. Endocr J. 2012;59(7):531-7. doi: 10.1507/endocrj.ej12-0069. Epub 2012 Mar 8. Endocr J. 2012. PMID: 22447136 Free article. Review.
Type 1 diabetes and autoimmunity.
Kawasaki E. Kawasaki E. Clin Pediatr Endocrinol. 2014 Oct;23(4):99-105. doi: 10.1297/cpe.23.99. Epub 2014 Nov 6. Clin Pediatr Endocrinol. 2014. PMID: 25374439 Free PMC article. Review.
Manufacturing of microarrays.
Petersen DW, Kawasaki ES. Petersen DW, et al. Among authors: kawasaki es. Adv Exp Med Biol. 2007;593:1-11. doi: 10.1007/978-0-387-39978-2_1. Adv Exp Med Biol. 2007. PMID: 17265711 Review.
Type 1 diabetes in Japan.
Kawasaki E, Matsuura N, Eguchi K. Kawasaki E, et al. Diabetologia. 2006 May;49(5):828-36. doi: 10.1007/s00125-006-0213-8. Epub 2006 Mar 28. Diabetologia. 2006. PMID: 16568259 Review.
New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): Report from Committee on Type 1 Diabetes of the Japan Diabetes Society (English version).
Shimada A, Kawasaki E, Abiru N, Awata T, Oikawa Y, Osawa H, Kajio H, Kozawa J, Takahashi K, Chujo D, Noso S, Fukui T, Miura J, Yasuda K, Yasuda H, Imagawa A, Ikegami H. Shimada A, et al. Among authors: kawasaki e. J Diabetes Investig. 2024 Feb;15(2):254-257. doi: 10.1111/jdi.14121. Epub 2024 Jan 7. J Diabetes Investig. 2024. PMID: 38184802 Free PMC article.
Genetics of fulminant type 1 diabetes.
Kawasaki E, Eguchi K. Kawasaki E, et al. Ann N Y Acad Sci. 2006 Oct;1079:24-30. doi: 10.1196/annals.1375.004. Ann N Y Acad Sci. 2006. PMID: 17130528 Review.
282 results